[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100451089":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":115,"collaborators":118,"id":129,"slug":10,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":130,"sex":136,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":10,"studyType":142,"phases":10,"briefSummary":143,"conditions":144,"keywords":149,"overallStatus":100,"whyStopped":10,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Pediatric Myeloablative allo-HSCT",null,"Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT.",{"label":13,"type":10,"description":14,"interventionNames":10},"Pediatric Standard Disease-Modifying Therapy","Participants ages 4 to 17 years old with SCD who receive standard therapy.",{"label":16,"type":10,"description":17,"interventionNames":10},"Adult Non-Myeloablative allo-HSCT","Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT.",{"label":19,"type":10,"description":20,"interventionNames":10},"Adult Standard Disease-Modifying Therapy","Participants ages 18 to 65 years old with SCD who receive standard therapy.",[22],{"name":23,"affiliation":5,"role":24},"Michael R DeBaun, MD, MPH","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Leshana Saint Jean, PhD","CONTACT","6158751992","leshana.saint.jean@vumc.org",{"name":32,"role":28,"phone":33,"phoneExt":10,"email":34},"Kristin Wuichet, PhD","6159366098","kristin.wuichet@vumc.org",[36,55,70,85,99],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Children's National Medical Center","NOT_YET_RECRUITING","Washington D.C.","District of Columbia","20010","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-77.03637,38.89511,{"lat":48,"lon":47},[51],{"name":52,"role":28,"phone":53,"phoneExt":10,"email":54},"Allistair Abraham, MD","202-476-6690","AAbraham@childrensnational.org",{"facility":56,"status":38,"city":57,"state":58,"zip":59,"country":42,"countryCode":43,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Emory University School of Medicine","Atlanta","Georgia","30322",{"type":45,"coordinates":61},[62,63],-84.38798,33.749,{"lat":63,"lon":62},[66],{"name":67,"role":28,"phone":68,"phoneExt":10,"email":69},"Vivien Sheehan, MD, PhD","404-727-7100","vivien.sheehan@emory.edu",{"facility":71,"status":38,"city":72,"state":73,"zip":74,"country":42,"countryCode":43,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Johns Hopkins Hospital","Baltimore","Maryland","21287",{"type":45,"coordinates":76},[77,78],-76.61219,39.29038,{"lat":78,"lon":77},[81],{"name":82,"role":28,"phone":83,"phoneExt":10,"email":84},"Richard Jones, MD","667-312-2400","rjjones@jhmi.edu",{"facility":86,"status":38,"city":87,"state":73,"zip":88,"country":42,"countryCode":43,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"National Institutes of Health Clinical Center","Bethesda","20814",{"type":45,"coordinates":90},[91,92],-77.10026,38.98067,{"lat":92,"lon":91},[95],{"name":96,"role":28,"phone":97,"phoneExt":10,"email":98},"Courtney Fitzhugh, MD","301-402-6496","courtney.fitzhugh@nih.gov",{"facility":5,"status":100,"city":101,"state":102,"zip":103,"country":42,"countryCode":43,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"RECRUITING","Nashville","Tennessee","37232-9000",{"type":45,"coordinates":105},[106,107],-86.78444,36.16589,{"lat":107,"lon":106},[110],{"name":111,"role":28,"phone":112,"phoneExt":113,"email":114},"Michael R. DeBaun, MD, MPH","615-875-3040","5-3040","m.debaun@vumc.org",{"type":24,"investigatorFullName":116,"investigatorTitle":117,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Michael DeBaun","Professor of Pediatrics and Medicine",[119,121,123,125,127],{"name":120,"class":6},"Johns Hopkins University",{"name":122,"class":6},"Children's National Research Institute",{"name":124,"class":6},"Emory University",{"name":126,"class":6},"University of Illinois at Chicago",{"name":128,"class":6},"Children's Healthcare of Atlanta","100451089",false,"NCT05153967","Cooperative Assessment of Late Effects for SCD Curative Therapies","U01 Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies","COALESCE","Inclusion Criteria\n\n* Confirmed laboratory diagnosis of SCD\n* Ability to give informed consent\n* Ability to provide pre- and post-curative therapy data\n* Treated with either one HSCT or with standard disease-modifying therapy\n\nExclusion Criteria\n\n•History of non-compliance","ALL","4 Years","65 Years",{"count":140,"type":141},750,"ESTIMATED","OBSERVATIONAL","Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \\>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.",[145,146,147,148],"Sickle Cell Disease","Pulmonary Disease","Renal Disease","Heart Disease",[150,151,152,153,154],"Myeloablative Autologous Gene Editing","Myeloablative Autologous Gene Therapy","Myeloablative allo-HSCT","Nonmyeloablative allo-HSCT","Disease-Modifying Therapy","2026-01-28",{"date":157,"type":158},"2026-01-30","ACTUAL",{"date":160,"type":158},"2022-07-12",{"date":162,"type":141},"2027-02",{"name":5,"class":6},5]